Federal Register / Vol. 72, No.
215 / Wednesday, November 7, 2007 / Notices
cultural, religious, or socioeconomic
status.
Documentation must be included in
the nomination to indicate that the
nominated individual is willing to serve
as a member of SACHRP. Individuals
who are selected to be considered for
appointment will be required to provide
detailed information regarding their
financial holdings, consultancies, and
research grants or contracts. Disclosure
of this information is necessary in order
to determine if the selected candidate is
involved in any activity that may pose
a potential conflict with the official
duties to be performed as a member of
SACHRP.
Dated: October 31, 2007.
Ivor A. Pritchard,
Acting Director, Office for Human Research
Protections, Acting Executive Secretary,
Secretary’s Advisory Committee on Human
Research Protections.
[FR Doc. E7–21824 Filed 11–6–07; 8:45 am]
BILLING CODE 4150–36–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on
Minority Health
AGENCY: Department of Health and
Human Services, Office of the Secretary,
Office of Public Health and Science,
Office of Minority Health.
ACTION: Notice.
SUMMARY: As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (DHHS) is hereby giving notice
that the Advisory Committee on
Minority Health (ACMH) will hold a
meeting. This meeting is open to the
public. Preregistration is required for
both public attendance and comment.
Any individual who wishes to attend
the meeting and/or participate in the
public comment session should e-mail
acmh@osophs.dhhs.gov.
The meeting will be held on
DATES:
November 27, 2007, from 9 a.m. to 4
p.m.
ADDRESSES: The meeting will be held at
the DoubleTree Hotel, Terrace Ballroom,
1515 Rhode Island Ave., NW.,
Washington, DC 20005. The meeting is
accessible from the Dupont Circle and
McPherson Square Metro Stations. From
the Dupont Circle Metro Station meeting
participants may walk 2 blocks south on
pwalker on PROD1PC71 with NOTICES
Connecticut Avenue, turn left on Rhode
Island Avenue for approximately 5
blocks. The DoubleTree is on the left
after Logan Circle. From the McPherson
Square Metro Station meeting
VerDate Aug<31>2005 16:14 Nov 06, 2007 Jkt 214001
62857
participants may walk 5 blocks north on
14th Street, turn right on to Rhode
Island Avenue for approximately 2
blocks. The DoubleTree will be on the
left after Logan Circle.
FOR FURTHER INFORMATION AND
REGISTRATION CONTACT: Ms. Monica
Baltimore, Tower Building, 1101
Wootton Parkway, Suite 600, Rockville,
Maryland 20852; phone: (240) 453–
2882; fax: (240) 453–2883.
SUPPLEMENTARY INFORMATION:
In accordance with Public Law 105–
392, the ACMH was established to
provide advice to the Deputy Assistant
Secretary for Minority Health in
improving the health of each racial and
ethnic minority group and on the
development of goals and specific
program activities of the Office of
Minority Health.
Topics to be discussed during this
meeting will include Integrating
Racially and Ethnically Diverse
Communities into Emergency
Preparedness and other strategies to
improve the health of racial and ethnic
minority populations through the
development of health policies and
programs that will help eliminate health
disparities, as well as other related
issues.
Public attendance at the meeting is
limited to space available. Individuals
who plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
designated contact person at least
fourteen business days prior to the
meeting. Members of the public will
have an opportunity to provide
comments at the meeting. Public
comments will be limited to five
minutes per speaker. Individuals who
would like to submit written statements
should mail or fax their comments to
the Office of Minority Health at least
five business days prior to the meeting.
Any members of the public who wish to
have printed material distributed to
ACMH committee members should
submit their materials to Garth N.
Graham, M.D., M.P.H., Executive
Secretary, ACMH, Tower Building, 1101
Wootton Parkway, Suite 600, Rockville,
Maryland 20852, prior to close of
business November 23, 2007.
Dated: October 30, 2007.
Garth N. Graham,
Deputy Assistant Secretary for Minority
Health.
[FR Doc. E7–21822 Filed 11–6–07; 8:45 am]
BILLING CODE 4150–29–P
PO 00000 Frm 00046 Fmt 4703 Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60 Day–07–07BS]
A. Proposed Data Collections Submitted
for Public Comment and
Recommendations; Notice
This 60 Day Federal Register Notice
published on September 27, 2007 (72 FR
54915–54916) has been inadvertently
republished. This is a duplicate
document of the previous FRN that was
published on October 27, 2006.
Therefore, we would like to retract it.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–21864 Filed 11–6–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): State Based
Occupational Safety and Health
Surveillance Review, Program
Announcement (PA) PAR04–106
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting.
Time and Date: 8 a.m.–5 p.m., November
30, 2007 (Closed).
Place: Renaissance Hotel, 6th Avenue,
Pittsburgh, PA 15222.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the review, discussion, and
evaluation of ‘‘State Based Occupational
Safety and Health Surveillance Review, PA
PAR04–106.
For Further Information Contact: Stephen
Olenchock, Ph.D., Scientific Review
Administrator, Office of Extramural
Coordination and Special Projects, National
Institute for Occupational Safety and Health,
CDC, 1095 Willowdale Road, Morgantown,
WV 26505, Telephone (304) 285–6271.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
E:\FR\FM\07NON1.SGM 07NON1
 62858 Federal Register / Vol. 72, No. 215 / Wednesday, November 7, 2007 / Notices

Dated: October 29, 2007. ACTION: Notice. SUPPLEMENTARY INFORMATION: The

Elaine L. Baker, holders of the applications listed in the
Director, Management Analysis and Services SUMMARY: The Food and Drug table in this document have informed
Office, Centers for Disease Control and Administration (FDA) is withdrawing FDA that these drug products are no
Prevention. approval of 73 new drug applications longer marketed and have requested that
[FR Doc. E7–21842 Filed 11–6–07; 8:45 am] (NDAs) and 62 abbreviated new drug FDA withdraw approval of the
BILLING CODE 4163–18–P applications (ANDAs) from multiple applications. The applicants have also,
applicants. The holders of the by their requests, waived their
applications notified the agency in opportunity for a hearing.
DEPARTMENT OF HEALTH AND
writing that the drug products were no
HUMAN SERVICES
longer marketed and requested that the
Food and Drug Administration approval of the applications be
withdrawn.
[Docket No. 2007N–0427]
EFFECTIVE DATE: December 7, 2007.
Lederle Laboratories et al.; Withdrawal FOR FURTHER INFORMATION CONTACT:
of Approval of 73 New Drug Florine P. Purdie, Center for Drug
Applications and 62 Abbreviated New
Evaluation and Research (HFD–7), Food
Drug Applications
and Drug Administration, 5600 Fishers
AGENCY: Food and Drug Administration, Lane, Rockville, MD 20857, 301–594–
HHS. 2041.

Application No. Drug Applicant

NDA 6–459 Hetrazan (diethylcarbamaxine citrate) Tablets and Syrup Lederle Laboratories, c/o Wyeth Pharmaceuticals, Inc.,
P.O. Box 8299, Philadelphia, PA 19101–8299

NDA 6–799 Rubramin and Rubramin PC (cyanocobalamin injection Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ
USP) 08543–4000

NDA 7–517 Tapazole (methimazole tablets USP), 5 milligrams (mg) King Pharmaceuticals, Inc., 501 Fifth St., Bristol, TN
and 10 mg 37620

NDA 7–942 Sus-Phrine (epinephrine) Injection Forest Laboratories, Inc., Harborside Financial Center,
Plaza Three, suite 602, Jersey City, NJ 07311

NDA 9–319 Ambenyl Expectorant and Ambenyl Cough Syrup Do.

NDA l0–533 PBZ SR (tripelennamine HCl USP) Extended-Release Novartis Pharmaceuticals Corp., One Health Plaza, East
Tablets Hanover, NJ 07936–1080

NDA 10–744 Darbid (isopropamide iodide) Tablets SmithKline Beecham Corp., d/b/a/ GlaxoSmith Kline, P.O.
Box 13398, Five Moore Dr., Research Triangle Park,
NC 27709

NDA 10–909 Miradon (anisindione) Tablets Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ
07033

NDA 11–213 Trilafon (perphenazine) Injection, 5 mg/milliliter (mL) Do.

NDA 11–283 Kenacort (tramcinolone) Tablets Bristol-Myers Squibb Co.

NDA 11–808 Mellaril (thioridazine HCl) Tablets Novartis Pharmaceuticals Corp.

NDA 12–145 Prolixin (fluphenazine HCl) Elixir, 0.5 mg/mL Apothecon, c/o Bristol-Myers Squibb Co., P.O. Box 4500,
Princeton, NJ 08543–4500

NDA 12–313 BIO-CLEAR (dibenzothiophene) Cream Helena Rubinstein, 202 Rodney Bldg., 3411 Silverside
Rd., Wilmington, DE 19810

NDA 12–665 Velban (vinblastine sulfate) for Injection Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN
46285

NDA 12–678 Tolbutamide Tablets Sandoz Inc., 227–15 North Conduit Ave., Laurelton, NY
11413

NDA 12–796 Quinidex Extentabs (quinidine sulfate extended-release Wyeth Pharmaceuticals, Inc.
pwalker on PROD1PC71 with NOTICES

tablets USP)

NDA 14–103 Oncovin (vincristine sulfate) Injection Eli Lilly and Co.

NDA 14–242 Dexacort (dexamethasone sodium phosphate) Turbinaire UCB, 755 Jefferson Rd., Rochester, NY 14623

VerDate Aug<31>2005 16:14 Nov 06, 2007 Jkt 214001 PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 E:\FR\FM\07NON1.SGM 07NON1